ICECAP: PROTOCOL AND PRACTICE OVERVIEW
ICECAP is a multicenter, randomized, adaptive allocation clinical trial to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest. This trial is funded by NIH and under FDA IDE G160072. The trial plans to enroll a maximum of 1,800 subjects over four years.

Study Population
Comatose adult survivors of out-of-hospital cardiac arrest (OHCA) that have already been rapidly cooled using a definitive temperature control method (endovascular or surface) will be enrolled in the emergency department or intensive care unit. Hub and spoke hospitals from the SIREN (Strategies to Innovate Emergency Care Clinical Trials) network will be enriched with high-potential ancillary Hubs.

Primary Efficacy Outcome
The primary outcome measure will be the modified Rankin scale (mRS) at 90 days after return of spontaneous circulation (ROSC). The mRS will be analyzed as a weighted score incorporating both the proportion of subjects achieving a good neurological outcome and degree of residual functional impairment among those with good neurological outcomes.

Primary Safety Outcomes
The primary safety outcome is all cause mortality at 90 days.

Second Safety Outcomes
Severe adverse events (SAEs) are monitored throughout the trial. They are anticipated to be related to therapeutic hypothermia and may include pneumonia, other infections (including urinary tract infections and bacteremia sepsis), malignant cardiac arrhythmia (cardiac arrest, ventricular fibrillation, ventricular tachycardia, atrial arrhythmias with hemodynamic compromise), seizures, neurological worsening, electrolyte abnormalities, venous thrombotic disease, and coagulopathies.

Inclusion
1. Coma after resuscitation from out-of-hospital cardiac arrest
2. Cooled to < 34°C within 240 minutes of cardiac arrest (from 911 call)
3. Definitive temperature control device initiated (must have closed-loop feedback)
4. Enrollment within 6 hours of initiation of cooling
5. Age ≥ 18 years
6. Informed consent from LAR, including intent to maintain life support for 96 hours

Exclusion
• Hemodynamic instability
• Preexisting neurological disability or condition that confounds outcome determination
• Preexisting terminal illness, unlikely to survive to outcome determination
• Planned early withdrawal of life support
• Presumed sepsis as etiology of arrest
• Prisoner

Randomization
Central computerized randomization by web-based interface will be used. Subjects will be potentially randomized over the course of the trial to the following possible durations of cooling (in hours): 6, 12, 18, 24, 30, 36, 42, 48, 60, and 72. The first 200 patients will be randomized 1:1:1 to the 12-, 24-, and 48-hour durations only.

Clinical Sites
Hub and spoke hospitals from the SIREN network will be enriched with high-potential ancillary Hubs, including some former Resuscitation Outcomes Consortium sites. The trial design anticipates needing at least 50 sites. ICECAP requires sites that can enroll an average of 9 subjects per year.

Study Intervention
The intervention for this trial is random allocation to duration of cooling after cardiac arrest (not target temperature or method of cooling).

Clinical Standardization
A team of national committee experts in neurocritical care, medical critical care, cardiology, and emergency medicine developed the ICECAP clinical standardization guidelines in accordance with the published guidelines of the AHA. The clinical standardization guidelines will be followed by investigation sites to reduce the effects of practice variability.

Temperature Management
Temperature Monitoring
Core temperature must be monitored continuously throughout cooling, rewarming, and controlled normothermia period.

Esophageal, bladder, or blood (e.g., pulmonary artery catheter) are the preferred sites for measuring core temperature. Rectal measurement of core temperature is less preferred, but is an acceptable alternative if other sites are not available. Bladder temperature sensors may be less reliable in anuric patients.

Use of two measurement sites/sources is preferred (e.g., esophageal and bladder temperature sensors).
Target Temperature
The target temperature during hypothermia is 33°C. Deviations from the target temperature should not exceed 1°C.

Rewarming
The target temperature at the end of rewarming is 36.5°C.

Rewarming will be done in a controlled manner using the temperature management device at a rate of about 0.15°C/hr (for those in groups 24 hours or more), or a rewarming period equal to the assigned arm if the assigned arm is shorter than 24 hours (6, 12, or 18 hours).

Duration of Cooling
Duration of cooling each subject will be obtained from randomization. Duration of cooling will be measured from the time that cooling with a definitive device is initiated in the hospital.

Cooling or Warming Methods
Hypothermia may be initiated with any combination of modality or device. A definitive device is defined as a closed-loop feedback endovascular or surface cooling device used to maintain therapeutic hypothermia and rewarming.

Why Consider Core Cooling Technology?
Data indicates there may be an interaction between quickness of cooling and duration of cooling that impacts efficacy. This study design attempts to minimize variability or limit the condition from time to target by restricting patients enrolled to those with relatively early and consistent induction of cooling.

Studies have shown that core cooling is a rapid and precise method compared to surface cooling. In a recent study, 100% of patients achieved target temperature of < 34°C within 3 hours compared to a surface cooling trial, in which only 50–71% of patients cooled below 34°C within 4 hours, despite additional cooling methods (i.e., ice packs) used and restricting patients weight for enrollment (> 250 lb excluded). Core cooling has no limitation or restriction on patients weights or heights since it cools from inside.

In addition, some populations (i.e., diabetics, peripheral vascular disease patients; those with poor nutritional status, steroid use, or high dose vasoressor therapy) are at higher risk of skin injury with a surface cooling device.

Temperature Management After Rewarming (Normothermia or Fever Prevention)
Controlled normothermia (36.5°C to 37.5°C) by active means is encouraged for 48 hours following rewarming in all subjects. Longer periods of controlled normothermia may be undertaken based on local practice. Whenever possible the definitive servo-control device (closed-loop feedback) should be continued to maintain normothermia.

Shivering Management
Shivering is a normal physiologic response to changes in temperature (cooling and rewarming). It may slow cooling or make it more difficult to accurately maintain the target temperature. In some cases, shivering may be difficult to distinguish from seizures. In those cases, EEG is necessary to diagnose seizures. Shivering should be assessed hourly using the Bedside Shivering Assessment Scale (BSAS).

Bedside Shivering Assessment Scale

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None: no shivering noted on palpation of the masseter, neck, or chest wall</td>
</tr>
<tr>
<td>1</td>
<td>Mild: shivering localized to the neck and/or thorax only</td>
</tr>
<tr>
<td>2</td>
<td>Moderate: shivering involves gross movements of the upper extremities (in addition to neck and thorax)</td>
</tr>
<tr>
<td>3</td>
<td>Severe: shivering involves gross movements of the trunk and upper and lower extremities</td>
</tr>
</tbody>
</table>

Interventions should be used as needed to maintain a BSAS < 1, or to prevent or respond to slow cooling or difficulty maintaining target temperature.

Shivering is often most intense during initial induction of hypothermia. Initial induction of hypothermia in this trial takes place prior to enrollment and randomization, so control of shivering during induction is therefore typically beyond the scope of the clinical standardization plan. During maintenance and rewarming, shivering should be addressed using a locally defined protocol (a suggested shivering management protocol follows).

If only assessing the presence or absence of shivering, especially with surface cooling, sites should record a BSAS=0 for no shivering and BSAS=2 for any shivering.
Physiological Goals and Management

**Blood Pressure**
Arterial blood pressure may be obtained noninvasively or by arterial line. Mean arterial pressure should be maintained to at least 65 mmHg. Interventions for a MAP below this boundary may be addressed based on clinical situation. Fluids, vasopressor, inotrope, or mechanical augmentation may be chosen alone or in combination based on the clinical situation.

**Oxygenation**
Pulse oximetry should be measured continuously. Arterial blood gas (ABG) should be measured only as needed. Oxygen saturation should be maintained greater than or equal to 94%, with supplemental oxygen or other means as needed, but supplemental oxygen should not be used if oxygen saturation is ≥98%.

Always reduce supplemental oxygen (FiO₂ > 0.21) to lowest level that maintains the hemoglobin oxygen saturation target (AHA Class I, LOE C).

Interventions for oxygenation below target includes increasing FiO₂ and optimizing ventilatory mode, rate, volume, or PEEP.

**Ventilation**
Normocapnia/normocarbia is preferred, unless there is an underlying lung pathology. PETCO₂ should be maintained at 35–40 mmHg (given variability in accuracy and calibration of this parameter, this will not be tracked as a transgression). Titrate tidal volume (initially 4–8 mL/kg) and ventilatory rate to maintain target Pa/ETCO₂ (AHA Class IIb, LOE C).

**Euglycemia**
Treatment of hypoglycemia or hyperglycemia will be dependent on local practice and the preferred target of serum glucose is between 80 to 180 mg/dL.

**Withdrawal From Active Intensive Care and Life Support**
Patients are ineligible for this study if there is early withdrawal of life support (within 5 days). All participants in the trial are expected to receive life support and active intensive care as needed for at least 96 hours after cardiac arrest (i.e., after rewarming from the longest possible duration of cooling to which participants may be allocated in the trial). An evaluation of neurologic prognosis will be performed on hospital day 5 for patients not regaining consciousness, which will inform subsequent withdrawal of life support decisions.

**Seizure Management**
An EEG for the diagnosis of seizure should be performed with prompt interpretation as soon as possible, but at least within the first 24 hours after ROSC. Continuous EEG (cEEG) is preferred, initiated as soon as possible and continued through rewarming. If cEEG is not available, then a repeat EEG during the second 24 hours after ROSC should be performed (AHA Class IIb, LOE C).

Treatment is mandated only for unequivocal, overt clinical or electrographic seizures (which in this population is status epilepticus by definition). Electrographic seizures should be treated as aggressively as the patient’s clinical status may safely tolerate. Other epileptiform activity is treated per local standards. Treatment should be as aggressive as possible to safely control seizures. Use of other antiepileptic medications is at the discretion of the attending physician.

**Infectious Complications**
Monitoring /Diagnosis
Daily chest X-ray and daily CBC, if desired by the treating team, are appropriate and may be used to screen for infection, especially during the period of intubation and cooling. Cultures should not be performed for monitoring or surveillance in the absence of clinical indications.

Cultures of blood, urine or sputum, and urinalysis should be performed based on specific indications.
Treatment
Prophylactic antibiotics to avoid ventilator-associated pneumonia are permitted but not required. When there is sufficient suspicion of infection, use and choice of antibiotics should be given consistent with institutional or clinical team preferences and local antibiotic susceptibilities.

Thrombotic Venous Complications
Prevention: DVT prophylaxis via SCDs, intermittent subcutaneous heparin, low molecular weight heparin, or other recommended prophylaxis pharmaceutical agents shall be instituted within 24 hours of ROSC, unless a contraindication exists.

No routine surveillance is suggested.

Treat with unfractionated or low molecular weight heparin with transition to oral anticoagulation as appropriate.

Management of Cardiac Interventions
PCI — This will be performed at the discretion of the local care team in accordance with AHA guidelines for early treatment of post-cardiac arrest patients, based on clinical suspicion, EKG findings, and cardiac biomarkers.

AICD — Placement of AICD will also be at the discretion of local clinical team.

### IVTM DEVICE INSTRUCTIONS FOR USE

**Equipment Needed:**
1. Thermogard XP®
2. IVTM™ Catheter Insertion Kit
3. IVTM StartUp Kit
4. 500 cc bag of sterile NS (NOT 1000 cc)
5. Patient temperature probe (see temperature monitoring recommendation)

**How to Select Cooling Catheter:**
- **Quattro®**: Fastest cooling rate (3.1°C/hr), preferred option, femoral placement, 45-cm length
- **Icy®**: Rapid cooling (2.1°C/hr), alternative option for femoral placement, 38-cm length
- **Solex 7®**: Fast cooling rate (1.8°C/hr) via internal jugular or subclavian vein placement; only select this if femoral approach is contraindicated

### Patient Weights and Heights

<table>
<thead>
<tr>
<th>Patient Weights and Heights</th>
<th>Catheter Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;120 lbs or &gt;5'1&quot;</td>
<td>Quattro catheter</td>
</tr>
<tr>
<td>&lt;120 lbs or &lt; 5'1&quot;</td>
<td>Icy catheter</td>
</tr>
</tbody>
</table>

**General Practice**

**Initiation Phase**
- All cooling catheters should be placed under Seldinger technique over a guidewire.
- Set the console for pre-cool and Max Power at the earliest opportunity.

**Induction Phase**
- Set the console in “Run” mode to start.
- Check to see if the pinwheel is spinning. If it is not spinning, check the following:
  - Air bubble may be in the flow indicator; flick the flow indicator to clear the bubble.
  - Catheter may be kinked; slightly reposition the catheter.
  - Tubing in the roller pump may have been loaded backwards; correct placement.
- Monitor patient; if there is shivering, treat per protocol.
- If the heater from a ventilator or continuous renal replacement therapy (CRRT) device interferes with cooling, turn off heater.

**Maintenance Phase**
- Monitor blood glucose, insulin level, polyuria, and electrolytes.
- Dressing should be changed if it becomes soiled, wet, or loose following hospital CVC protocol.
- Medication administration should be considered via IV or one of the infusion ports of cooling catheter (has triple lumen CVC function). Oral, nasogastric, or subcutaneous administration may be affected during cooling based on the degree of hepatic metabolism, first pass effect, and absorption impairment.

**Rewarming Phase**
- Anticipate hyperkalemia, hypercalcemia, hypoglycemia, hypotension, hypovolemia, and decreased SVR.
- Paralysis and sedation should be weaned.
- Cooling catheter can be discontinued after rewarming if used to maximum indwell period.
- Maintain normothermia or fever avoidance by either ZOLL® STx™ surface cooling or exchange to another cooling catheter (also with CVC function).
- Cooling catheter is removed and disposed per hospital guidelines for CVC. Ensure that the catheter inflow and outflow lumens (orange color) are open prior to removing the catheter in order to allow residual saline to be expelled from the catheter balloons.
7. If a patient's temperature is below 33°C at hospital arrival, what target temperature should be used?
• Below is a list of suggested approaches per Harborview Medical Center protocol. It is not a recommendation from the company. It may or may not fit your hospital situation. Please follow your own hospital protocol if applicable.

<table>
<thead>
<tr>
<th>Temperature Range</th>
<th>Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;30°C (rare)</td>
<td>Therapy to 30°C using Max Power</td>
</tr>
<tr>
<td></td>
<td>• Select Pre-warm</td>
</tr>
<tr>
<td></td>
<td>• Set TGXP target temperature to 30°C</td>
</tr>
<tr>
<td></td>
<td>• Select Max Power mode of treatment</td>
</tr>
<tr>
<td></td>
<td>• Set TGXP &quot;HI&quot; temperature alarm limit to 30°C</td>
</tr>
<tr>
<td>30–33°C and</td>
<td>Therapy to 33°C using Max Power</td>
</tr>
<tr>
<td>hemodynamically</td>
<td>• Select Pre-warm</td>
</tr>
<tr>
<td>unstable (rare)</td>
<td>• Set TGXP target temperature to 33°C</td>
</tr>
<tr>
<td></td>
<td>• Select Max Power mode of treatment</td>
</tr>
<tr>
<td>30–33°C and</td>
<td>Therapy to 33°C using Controlled Rate</td>
</tr>
<tr>
<td>hemodynamically</td>
<td>• Select Pre-warm</td>
</tr>
<tr>
<td>stable (rare)</td>
<td>• Set TGXP target temperature to 33°C</td>
</tr>
<tr>
<td></td>
<td>• Select Controlled Rate mode of treatment and rewarm patient at a rate of 0.15°C/hr</td>
</tr>
</tbody>
</table>

8. Can the patient be placed on continuous renal replacement therapy (CRRT) during hypothermia therapy?
• Yes. Follow hospital protocol for CRRT. If the institution’s CRRT equipment doesn’t have a heater as part of its system, it may cause a slower rewarming rate. If this occurs, place warm blankets or an air warming blanket over the patient; turn the heater on the ventilator to 37°C.

References:
Information regarding the ICECAP Trial can be found here: https://siren.network/clinical-trials/icecap

MCN 19 2010 0280
1044346-001, Rev. 02